MS

Maninder Singh

Director Director DIN 01435137
DIN 01435137 First appointment May 2005 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2005
Shareholding value •••• Premium profile

About Maninder Singh

Data last updated:

Maninder Singh was a Director at Onyx Biotec Limited (2005–2008) and Director at Ravenbhel Health Care Private Limited (2013–2020). The companies operate in Chemicals and Pharma.

DIN 01435137
Primary Designation Director
Industry Chemicals
First Appointment 13 May 2005

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Onyx Biotec Limited L24230HP2005PLC028403
Director13 May 20052005₹63.12 Cr (FY 2025)Active
Director13 Feb 20132003₹291 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Onyx Biotec Limited
Ravenbhel Health Care Private Limited
Premium access

Shareholding and investment profile for Maninder Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Maninder Singh

Maninder Singh was first appointed on 13 May 2005 as Director at Onyx Biotec Limited. The most recent appointment on record is 13 Feb 2013 at Ravenbhel Health Care Private Limited.

Maninder Singh held 2 earlier board appointments: Onyx Biotec Limited (Director, 13 May 2005 to 27 May 2008); Ravenbhel Health Care Private Limited (Director, 13 Feb 2013 to 19 Feb 2020).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available